SHANGHAI/BEIJING, Nov 14 (Reuters) – A CAR-T cancer therapy developed by drugmaker JW Therapeutics will be added to China’s state-run health insurance scheme from January 1, the National Healthcare Security Administration said on Saturday.
The CAR-T therapy, which engineers patients’ immune cells to recognise and kill cancer cells, was included on the list for the first time.
(Reporting by Andrew Silver and Beijing newsroom; Editing by William Mallard)
